368
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Effect of Pineapple Juice on the Pharmacokinetics of Celecoxib and Montelukast in Humans

ORCID Icon, ORCID Icon & ORCID Icon
Pages 301-311 | Received 27 Feb 2020, Accepted 11 May 2020, Published online: 08 Jun 2020
 

Abstract

Aim: To study the influence of pineapple juice on the pharmacokinetics of celecoxib and montelukast in humans. Experimental methods: The research comprised two separate arms. Each arm was randomized, two-crossover periods separated by a 2-week washout period. Subjects received a single dose of celecoxib or montelukast after pretreatment with either water or pineapple juice for 4 days before the study beginning. Results & conclusion: Pineapple juice enhanced the systemic exposure of both drugs without any noticeable adverse effects. For celecoxib, Cmax and AUC0–∞ were increased significantly by 40 and 60%, respectively. Cl/F was decreased by 45% without affecting its t1/2. For montelukast, Cmax and AUC0–∞ were significantly increased by 21 and 48%, respectively, along with 25% decrease in clearance and 13% increase in t1/2.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained a ClinicalTrials.gov Identifier NCT04374981 and have followed the principles outlined in the Declaration of Helsinki for human experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from all the participants involved.

Data sharing statement

The authors certify that this manuscript reports original clinical trial data, NCT 04374981. Individual participant data that underlies the results reported in the article, after de-identification (text, tables, figures and supplement) are available along with the study protocol. The data will be available from the date of online article publication. Proposals to access data will be available to anyone who wishes to access the data, for any purpose by any mechanism.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.